Phosphodiesterase 5 inhibitors: are they cardioprotective?

Cardiovascular Research

Volumn 83, Issue 2, 2009, Pages 204-212

  Reffelmann, Thorsten ^a,b   Kloner, Robert A ^b  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Phosphodiesterase 5; Preconditioning; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

CYCLIC GMP PHOSPHODIESTERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHODIESTERASE V; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

CARDIOTOXICITY; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME MECHANISM; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; IN VIVO CULTURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SYSTOLIC HEART FAILURE; TISSUE DISTRIBUTION;

ANIMALS; CARDIOMEGALY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 67650266514     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp170     Document Type: Review

References (76)

1. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 2006;12:3485-3494.
2. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000;86: 57F-61F.
3. Feenstra J, van Drie-Pierik RJ, Lacle CF, Strieker BH. Acute myocardial infarction associated with sildenafil. Lancet 1998;352:957-958.
4. Porter A, Mager A, Birnbaum Y, Strasberg B, Sclarovsky S, Rechavia E. Acute myocardial infarction following sildenafil citrate (Viagra) intake in a nitrate-free patient. Clin Cardiol 1999;22:762-763.
5. Przyklenk K, Kloner RA. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. JAm Coll Cardiol 2001;37:286-292.
6. Traverse JH, Chean YJ, Du R, Bache RJ. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation 2000;102:2997-3002.
7. Herrmann HC, Chang G, Klugherz B, Mahoney PD. Hemodynamic effects of Sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-1626.
8. Geelen P, Drolet B, Rail J, Berube J, Daleau P, Rousseau G et al. Sildenafil citrate (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000;102:275-277.
9. Swissa M, Ohara T, Lee MH, Kaul S, Shah PK, Hayashi H et al. Sildenafilnitric oxide donor combination promotes ventricular tachyarrhythmia in the swine right ventricle. Am J Physiol Heart Circ Physiol 2002;282: H1787-H1792.
10. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002;89:1331-1334.
11. Kloner RA. Cardiovascular effects of 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110:3149-3155.
12. Kloner RA, Mohan P, Segerson T. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled trials. J Am Coll Cardiol 2003;41(Suppl. A): 276A-277A.
13. Kloner RA, Jackson G, Hutter AM, Mittleman MA, Chan M, Warner MR et al. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006;97:1778-1784.
14. Reffelmann T, Kloner RA. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf 2005;4:531-540.
15. Reffelmann T, Kieback A, Kloner RA. The cardiovascular safety of tadalafil. Expert Opin Drug Saf 2008;7:43-52.
16. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinmann KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachussetts Male Aging Study. J Urol 2000;163:460-463.
17. Gross GJ. Sildenafil and endothelial dysfunction in humans. Circulation 2005;111:721-723.
18. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient. Endothelial dysfunction is the common denominator. Heart 2003;89:251-253.
19. Kaiser DR, Billups K, Mason C, Wetterling R, Lungberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004;43:179-184.
20. Maas R, Schwedhelm E, Albsmeier J, Borger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002;7:213-225.
21. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003;108:239- 244.
22. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S et al. Guanylyl cyclases and signalling by cyclic GMP. Pharmacol Rev 2000;52:375-414.
23. Su J, Scholz PM, Weiss HR. Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med 2005;230:242-250.
24. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA et al. Compartmentalization of cardiac ß-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 2007;115:2159-2167.
25. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effect of Sildenafil on tissue cyclic nucleotides, platelet function, and the contractile response of trabeculae carneae and aortic rings. Am J Cardiol 1999;83:3C-12C.
26. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of Sildenafil citrate. Am J Cardiol 1999;83:35C-44C.
27. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003;92(Suppl.):37M-46M.
28. Ghofrani HA, Voswinckel R, Reichenberger R, Olschewski H, Haredza P, Karadas P et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2004;44:1488-1496.
29. Steiner MK, Preston IR, Klinger JR, Hill NA. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 2005;5:245-250.
30. Fox KM, Thadani U, Ma PT, Nash SD, Keating Z, Czomiak MA et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003;24:2206- 2212.
31. Halcox JPJ, Nour KRA, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002;40:1232-1240.
32. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates ß-adrenergic signalling in vivo and is down-regulated in heart failure. FASEB J 2001;15:1718-1726.
33. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of nitric oxide signalling. J Biol Chem 2005;280:12944-12955.
34. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene 1998;216:139-147.
35. Stief CG, Ückert S, Becker AJ, Harringer W, Truss MC, Forssmann WG et al. Effects of Sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000;55:146-150.
36. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005;96:100-109.
37. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits ß-adrenergic-stimulated cardiac contractility in humans. Circulation 2005;112:2642-2649.
38. Castro LRV, Verde I, Cooper DMF, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac monocytes. Circulation 2006;113:2221-2228.
39. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 2002;283:H1263-H1269.
40. Das S, Maulik N, Das DK, Kadowitz RJ, Bivalacqua TJ. Cardioprotection with sildenafil, a selective inhibitor of cyclic 3',5'-monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res 2002;28:213-219.
41. du Toit EF, Rossow E, Salie R, Opie LH, Lochner A. Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 2005;19:23-31.
42. Reffelmann T, Kloner RA. Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res 2003;59:441-449.
43. ATP-channels in rabbits. J Mol Cell Cardiol 2006;40:405-411.
44. Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A et al. Cardioprotection with phosphodiesterse-5 inhibition-a novel preconditioning strategy. J Mol Cell Cardiol 2004;36:165-173.
45. Sesti C, Florio V, Johnson EG, Kloner RA. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 2007; 19:55-61.
46. Das A, Ockaili R, Salloum F, Hawkins J, Kukreja RC. Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 2004;286:H1455-H1460.
47. Das A, Xi L, Kukreja RC. Protein kinase G-dependent cardioprotective mechanisms of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 2008;283:29572-29585.
48. Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2009;296:H1236-H1243.
49. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA. Sustained soluble guanylate cyclase stimulation offsets nitric oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther 2008;326:380-387.
50. Jamnicki-Abgegg M, Weihrauch D, Chiari PC, Krolikowski JG, Pagel PS, Warltier DC et al. Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection. J Cardiovasc Pharmacol 2007;50:670-676.
51. Elrod JW, Greer JM, Lefer DJ. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol 2007;292:H342-H347.
52. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007;101:1084-1095.
53. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999;84:1020-1031.
54. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphdiesterases and implications for cardiac pathophysiology. Circ Res 2007;100:1569-1578.
55. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 2006;70:200-211.
56. Salloum FN, Takenoshita Y, Ockaili RA, Daoud V, Chou E, Yoshida K et al. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondiral KATP channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 2007;42:453-458.
57. Maas O, Donat U, Frenzel M, Rütz T, Kroemer HK, Felix SB et al. Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. Br J Pharmacol 2008;154:25-31.
58. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase G in myocardial ischemia and reperfusion: opportunities and obstacles for survival signalling. Br J Pharmacol 2007;152:855-869.
59. Salloum F, Ying C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003;92:595-597.
60. Wang Y, Guo Y, Zahng SX, Wu W-J, Wang J, Bao W et al. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. J Mol Cell Cardiol 2002;34:5-15.
61. Salloum FN, Das A, Thomas CS, Yin C, Kukreja RC. Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Mol Cell Cardiol 2007;43:545-551.
62. Rosanio S, Ye Y, Atar S, Rahan AM, Freeberg SY, Huang MH et al. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 2006;20:5-8.
63. Salloum FN, Abbated A, Das A, Houser JE, Mudrick CA, Qureshi IZ et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 2008; 294:H1398-H1406.
64. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterse-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111:1601-1610.
65. Chen Y, Traverse JH, Hou M, Li Y, Bache RJ. Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2003;284:H1513-H1520.
66. Takimoto E, Champion HC, Belardi D, Ren S, Rodriguez ER, Bedia D et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-222.
67. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedia D, Gabrielson KL et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 2009;53:207-215.
68. Hsu S, Nagayama T, Koitabashi N, Zhang M, Zhou L, Bedjy D et al. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 2009;81:301-309.
69. Ferreira-Melo SE, Yugar-Toledo JC, Coelho OR, De Luca IM, Tanus-Santos JE, Hyslop S et al. Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. Eur J Pharmacol 2006;542:141-147.
70. Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-222.
71. Jackson G. Phosphodiesterase type 5 inhibition in cardiovascular disease: experimental models and potential clinical applications. Eur Heart J 2002;4(Suppl. H):19-23.
72. Hirate K, Adji A, Vlachopopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005; 96:1436-1440.
73. Bocchi EA, Guimarães C, Mocelin A, Bacal F, Belotti G, Ramires JF. Sildenafil effects on exercise, neurohumoral activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-1103.
74. Product monograph for Levitra (vardenafil HCL), Bayer Health Care, Glaxo SmithKline, 2003.
75. Piccirillo G, Nocco M, Lionetti M, Moise A, Naso C, Marigliano V et al. Effects of sildenafil citrate (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002;143:703-710.
76. Phillips BG, Kato M, Pesek CA, Winnicki M, Nrkiewicz K, Davison D. Sympathetic activation by sildenafil. Circulation 2000;102:3068- 3073.